We are deeply disappointed that the U.S. House of Representatives has voted to advance the BIOSECURE Act. The bill is a false flag targeting companies under the premise of national security, but in reality it will strengthen the monopoly in the genomics market held by one dominant U.S. player that has been lobbying for the bill.
We reiterate that BGI poses no national security risks, that we strictly follow rules and laws, and we have no access to Americans’ personal data in any of our work. We are disappointed that the U.S. legislative process is being used to pick winners and losers.
BGI Group’s previous statements on the bill